<DOC>
	<DOCNO>NCT00267943</DOCNO>
	<brief_summary>The primary objective ass efficacy safety fix dose combination telmisartan 80 mg + hydrochlorothiazide 25 mg ( T80/H25 ) alone addition antihypertensive therapy open-label , long-term treatment .</brief_summary>
	<brief_title>Open-label Follow-up Trial Fixed Dose Combination Telmisartan + Hydrochlorothiazide Hypertensive Patients</brief_title>
	<detailed_description>Patients history hypertension complete precede trial ( number 502.480 ) within previous fourteen ( 14 ) day consider entry long-term open-label trial . All patient receive 'T80/H25 ' . Additional antihypertensive therapy allow patient ' blood pressure well control . [ In precede double-blind trial 502.480 , patient fail respond fix dose combination telmisartan 80 mg '+ ' hydrochlorothiazide 12.5 mg ( T80/H12.5 ) randomise 'T80/H12.5 ' T80H25 eight week . ] This multi-centre , multinational trial approximately 80 study centre participate . Only study centre participate precede trial 502.480 enter patient open-label trial . It anticipate maximum 480 patient enter trial seventeen country . Each trial centre expect enter four twenty-four patient . Enrollment patient trial finish last patient completes precede trial 502.480 . At time , centre notify termination recruitment authorize include patient . Patients visit clinic one month , three month six month later assessment blood pressure general health . Their participation study complete six month start treatment period . Study Hypothesis : No statistical hypothesis test . Descriptive statistic use characterise effect treatment T80/H25 without antihypertensive treatment . Comparison ( ) : The proportion patient achieve DBP control summarise total number patient trial well maximum achieve dose level accord two category T80/H25 alone ( T80/H25 ) antihypertensive medication add ( T80/H25/other ) . An additional sub-group summary treatment group precede trial 502.480 ( T80/H12.5 T80/H25 ) also present .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Telmisartan , hydrochlorothiazide drug combination</mesh_term>
	<criteria>Inclusion criterion : Essential hypertension . Currently take one three antihypertensive medication stable dose least four week Visit 1 precede trial 502.480 . Blood pressure adequately control exist treatment entry precede trial 502.480 ( inadequate control define seat DBP &gt; = 95 mmHg one current antihypertensive medication DBP &gt; = 90 mmHg two current antihypertensive medication ) . Failure respond six week runin treatment T80/H12.5 precede trial 502.480 . ( Failure respond define seat DBP &gt; = 90 mmHg . ) Willing able provide write informed consent . Exclusion criterion : Women childbearing potential NOT practise acceptable mean birth control , positive serum pregnancy test , breastfeed . Known suspected secondary hypertension . Clinically significant change ECG report adverse event precede trial 502.480 . Any medical condition develop precede trial 502.480 could worsen telmisartan/HCTZ ( 80/25 ) . Discontinuation precede 502.480 trial adverse event reason . Mean SBP &gt; = 200 mmHg . Severe hepatic renal impairment . Bilateral renal artery stenosis ( solitary kidney ) , postrenal transplant one functioning kidney . Clinically relevant hypokalaemia hyperkalaemia . Uncorrected volume sodium depletion , primary aldosteronism . Hereditary fructose intolerance . Previous symptom angioedema ACE inhibitor angiotensinII receptor antagonist . Drug alcohol dependency within six month prior entry 502.480. concurrent participation another clinical trial investigational therapy . Hypertrophic obstructive cardiomyopathy , hemodynamically relevant stenosis aortic mitral valve . Allergic hypersensitivity component formulation investigation . Concomitant therapy lithium , cholestyramine colestipol resin . Noncompliance study medication ( le 80 % 120 % ) precede 502.480 trial . Any clinical condition , opinion investigator , would allow safe administration telmisartan hydrochlorothiazide .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>